NASDAQ: NUVLNuvalent Inc Stock Ownership - Who owns Nuvalent?
Insider buying vs selling
Have Nuvalent Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Alexandra Balcom | Chief Financial Officer | 2025-07-16 | 14,700 | $85.10 | $1.25MSell |
| Alexandra Balcom | Chief Financial Officer | 2025-07-16 | 14,700 | $18.93 | $278.27kBuy |
| James Richard Porter | President and CEO | 2025-07-15 | 104 | $84.53 | $8.79kSell |
| James Richard Porter | President and CEO | 2025-07-15 | 27,000 | $18.93 | $511.11kBuy |
| Alexandra Balcom | Chief Financial Officer | 2025-07-15 | 54 | $85.48 | $4.62kSell |
| Alexandra Balcom | Chief Financial Officer | 2025-07-15 | 874 | $84.91 | $74.21kSell |
| Alexandra Balcom | Chief Financial Officer | 2025-07-15 | 1,888 | $83.87 | $158.35kSell |
| Alexandra Balcom | Chief Financial Officer | 2025-07-15 | 2,484 | $82.67 | $205.35kSell |
| James Richard Porter | President and CEO | 2025-07-15 | 1,496 | $83.94 | $125.57kSell |
| Alexandra Balcom | Chief Financial Officer | 2025-07-15 | 5,300 | $18.93 | $100.33kBuy |
NUVL insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when NUVL insiders and whales buy or sell their stock.
NUVL Shareholders
What type of owners hold Nuvalent Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| James E. Flynn | 25.97% | 18,646,022 | $1.48B | Insider |
| Deerfield Management Company LP Series C | 25.05% | 17,991,024 | $1.43B | Institution |
| Fmr LLC | 13.84% | 9,937,193 | $790.40M | Institution |
| Paradigm Biocapital Advisors LP | 7.34% | 5,269,433 | $419.13M | Institution |
| Vanguard Group Inc | 6.18% | 4,439,838 | $353.14M | Institution |
| Blackrock Inc | 5.22% | 3,748,361 | $298.14M | Institution |
| Commodore Capital LP | 2.58% | 1,855,000 | $147.55M | Institution |
| Matthew Shair | 2.29% | 1,646,366 | $130.95M | Insider |
| Perceptive Advisors LLC | 2.28% | 1,633,968 | $129.97M | Institution |
| Price T Rowe Associates Inc | 2.02% | 1,450,602 | $115.38M | Institution |
NUVL vs Biotech Stocks
Nuvalent Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.